Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 5/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 4/20 | 0.34 |
| ▸ | CA1 | P00915 | 4/20 | 0.34 |
| ▸ | CA2 | P00918 | 4/20 | 0.34 |
| ▸ | CA9 | Q16790 | 4/20 | 0.34 |
| ▸ | F9 | P00740 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | NQO1 | P15559 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19082387 | 0.93 | CYP1A1 (0.35) | CYP1A1CYP1B1CYP1A2CA12CA1 | |
| SCHEMBL17944201 | 0.93 | ALOX5 (0.39) | CA12CA1CA2CA9F9 | |
| SCHEMBL19082239 | 0.88 | CA12 (0.38) | CYP1A1CYP1B1CYP1A2CA12CA1 | |
| SCHEMBL17944678 | 0.87 | ALOX5 (0.39) | CA12CA1CA2CA9ALOX5 | |
| SCHEMBL19082349 | 0.86 | CYP1A1 (0.39) | CYP1A1CYP1B1CYP1A2F9ALOX5 | |
| SCHEMBL19082190 | 0.86 | CYP1A1 (0.40) | CYP1A1CYP1B1CYP1A2F9NQO1 | |
| SCHEMBL19082142 | 0.86 | CYP1A1 (0.35) | CYP1A1CYP1B1CYP1A2NQO1NQO2 | |
| SCHEMBL17945706 | 0.86 | CA12 (0.40) | CYP1A1CYP1B1CYP1A2CA12CA1 | |
| SCHEMBL17945525 | 0.85 | ALOX5 (0.38) | CYP1A1CYP1B1CA12CA1CA2 | |
| SCHEMBL19080253 | 0.84 | CYP1A1 (0.40) | CYP1A1CYP1B1CYP1A2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170194572-A1 | CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-07-06 | — | — | US | disclosed |
| US-20170194572-A1 | CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170194572-A1 | CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CRY2, CCNT1 | CYP1A1 184/4885CYP1B1 260/4885CYP1A2 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.